z-logo
Premium
Association between UDP ‐glucuronosyltransferase 2B7 tag SNP s and breast cancer risk in Chinese females
Author(s) -
He BaoXia,
Qiao Bin,
Lam Alfred KingYin,
Zhao XiuLi,
Zhang WenZhou,
Liu Hui
Publication year - 2018
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12908
Subject(s) - breast cancer , genotype , single nucleotide polymorphism , allele , medicine , haplotype , oncology , odds ratio , snp , cancer , endocrinology , biology , genetics , gene
Summary This retrospective study was performed to evaluate the association between the UGT 2B7 tag SNP s (rs12233719, rs4356975, rs7435335 and rs7441774) and breast cancer in Chinese females. Blood samples were collected from 672 patients with breast cancer and 670 healthy controls for DNA extraction. Matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry ( MALDI ‐ TOF MS ) was used to analyze UGT 2B7 polymorphisms. Dual‐luciferase reporter assays were further performed to investigate the regulatory function of UGT 2B7 tag SNP s. The frequency of rs7441774 G allele in the breast cancer cases was statistically significantly higher than in the controls (0.412 vs 0.358, P  = .006; odds ratio [ OR ] = 1.27, 95% CI  = 1.08‐1.48). After adjusting for conventional risk factors, individuals with the GG genotype had a higher breast cancer risk than those with the AA genotype (adjusted OR  = 1.63, 95% CI  = 1.18‐2.26; P  = .008). The GCGG haplotype of UGT 2B7 was also associated with breast cancer ( OR  = 1.22, 95% CI  = 1.04‐1.45; P  = .027). Meanwhile, the rs7441774 G allele could significantly decrease the transcriptional activity of the UGT 2B7 gene. This study indicates that UGT 2B7 polymorphisms may play a crucial role in the occurrence and development of breast cancer in the Han Chinese population.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here